Suchergebnisse - "Vanden Abeele, Carline"

PubPharm (11)

1

The RSVPreF3-AS01 vaccine elicits broad neutralization of contemporary and antigenically distant respiratory syncytial virus strains

enthalten in: Science translational medicine | 2023

von Sacconnay, L. | De Smedt, J. | Rocha-Perugini, V. | +14

2

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults : Phase 1/2 Randomized Clinical Trial

enthalten in: The Journal of infectious diseases | 2023

von Leroux-Roels, I. | Davis, M. | Steenackers, K. | +19

3

Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted : a phase 1-2 randomised controlled trial

enthalten in: The Lancet. Infectious diseases | 2022

von Folschweiller, N. | Vanden Abeele, C. | Chu, L. | +17

CommentIn: Lancet Infect Dis. 2022 Jul;22(7):926-928. - PMID 35461523

4

Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults : Results of a phase III, randomized, open-label, multicenter study

enthalten in: Vaccine | 2018

von Lal, H. | Poder, A. | Campora, L. | +4

5

A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su

enthalten in: Vaccine | 2017

von Strezova, A. | Godeaux, O. | Aggarwal, N. | +7

6

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

enthalten in: The New England journal of medicine | 2016

von Cunningham, A. | Lal, H. | Kovac, M. | +129

CommentIn: N Engl J Med. 2016 Sep 15;375(11):1079-80. - PMID 27626522

7

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

enthalten in: The New England journal of medicine | 2016

von Cunningham, A. | Lal, H. | Kovac, M. | +28

8

Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years : follow-up of safety and immunogenicity persistence at 24 months post-vaccination

enthalten in: Influenza and other respiratory viruses | 2015

von Díez-Domingo, J. | Baldó, J. | Planelles-Catarino, M. | +9

9

Phase II, randomized, open, controlled study of AS03‐adjuvanted H5N1 pre‐pandemic influenza vaccine in children aged 3 to 9 years: follow‐up of safety and immunogenicity persistence at 24 months post‐vaccination

enthalten in: Influenza and other respiratory viruses | 2015

von Díez‐Domingo, J. | Baldó, J. | Planelles‐Catarino, M. | +9

10

A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months

enthalten in: Human vaccines & immunotherapeutics | 2014

von Carmona Martinez, A. | Salamanca de la Cueva, I. | Boutet, P. | +3